Cargando…

Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases—a phase II, single centre, randomised, pilot study

INTRODUCTION: Patients with in-transit melanoma metastases present a therapeutic challenge. Complete surgical excision of localised disease is considered as the gold standard; however, surgery is not always acceptable and alternatives are required. Treatment results reported using imiquimod and diph...

Descripción completa

Detalles Bibliográficos
Autores principales: Read, Tavis, Webber, Scott, Thomas, Janine, Wagels, Michael, Schaider, Helmut, Soyer, H Peter, Smithers, B Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640002/
https://www.ncbi.nlm.nih.gov/pubmed/28988173
http://dx.doi.org/10.1136/bmjopen-2017-016816
_version_ 1783270967668113408
author Read, Tavis
Webber, Scott
Thomas, Janine
Wagels, Michael
Schaider, Helmut
Soyer, H Peter
Smithers, B Mark
author_facet Read, Tavis
Webber, Scott
Thomas, Janine
Wagels, Michael
Schaider, Helmut
Soyer, H Peter
Smithers, B Mark
author_sort Read, Tavis
collection PubMed
description INTRODUCTION: Patients with in-transit melanoma metastases present a therapeutic challenge. Complete surgical excision of localised disease is considered as the gold standard; however, surgery is not always acceptable and alternatives are required. Treatment results reported using imiquimod and diphenylcyclopropenone (DPCP) suggest that topical immunotherapies can be used to successfully treat select patients with melanoma metastases. A phase II, randomised, single centre, pilot study was designed to assess the clinical efficacy and safety of DPCP and imiquimod for the treatment of superficial, cutaneous in-transit melanoma metastases. METHODS AND ANALYSIS: This is an open-label, non-superiority, pilot study with no treatment cross-over. Eligible patients are randomised in a 1:1 ratio to receive topical therapy for up to 12 months with a minimum follow-up period of 12 months. The target sample size is 30 patients, with 15 allocated to each treatment arm. The primary endpoint is the number of patients experiencing a complete response of treated lesions as determined clinically using Response Evaluation Criteria in Solid Tumours. This trial incorporates health-related quality of life measures and biological tissue collection for further experimental substudies. The study will also facilitate a health economic analysis. ETHICS AND DISSEMINATION: Approval was obtained from the Human Research Ethics Committee at the participating centre, and recruitment has commenced. The results of this study will be submitted for formal publication within a peer-reviewed journal. TRIAL REGISTRATION NUMBER: Prospectively registered on 16 October 2015 with the Australian New Zealand Clinical Trials Registry (ACTRN12615001088538). This study conforms to WHO Trial Registration Data Set.
format Online
Article
Text
id pubmed-5640002
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-56400022017-10-19 Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases—a phase II, single centre, randomised, pilot study Read, Tavis Webber, Scott Thomas, Janine Wagels, Michael Schaider, Helmut Soyer, H Peter Smithers, B Mark BMJ Open Oncology INTRODUCTION: Patients with in-transit melanoma metastases present a therapeutic challenge. Complete surgical excision of localised disease is considered as the gold standard; however, surgery is not always acceptable and alternatives are required. Treatment results reported using imiquimod and diphenylcyclopropenone (DPCP) suggest that topical immunotherapies can be used to successfully treat select patients with melanoma metastases. A phase II, randomised, single centre, pilot study was designed to assess the clinical efficacy and safety of DPCP and imiquimod for the treatment of superficial, cutaneous in-transit melanoma metastases. METHODS AND ANALYSIS: This is an open-label, non-superiority, pilot study with no treatment cross-over. Eligible patients are randomised in a 1:1 ratio to receive topical therapy for up to 12 months with a minimum follow-up period of 12 months. The target sample size is 30 patients, with 15 allocated to each treatment arm. The primary endpoint is the number of patients experiencing a complete response of treated lesions as determined clinically using Response Evaluation Criteria in Solid Tumours. This trial incorporates health-related quality of life measures and biological tissue collection for further experimental substudies. The study will also facilitate a health economic analysis. ETHICS AND DISSEMINATION: Approval was obtained from the Human Research Ethics Committee at the participating centre, and recruitment has commenced. The results of this study will be submitted for formal publication within a peer-reviewed journal. TRIAL REGISTRATION NUMBER: Prospectively registered on 16 October 2015 with the Australian New Zealand Clinical Trials Registry (ACTRN12615001088538). This study conforms to WHO Trial Registration Data Set. BMJ Publishing Group 2017-10-06 /pmc/articles/PMC5640002/ /pubmed/28988173 http://dx.doi.org/10.1136/bmjopen-2017-016816 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Oncology
Read, Tavis
Webber, Scott
Thomas, Janine
Wagels, Michael
Schaider, Helmut
Soyer, H Peter
Smithers, B Mark
Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases—a phase II, single centre, randomised, pilot study
title Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases—a phase II, single centre, randomised, pilot study
title_full Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases—a phase II, single centre, randomised, pilot study
title_fullStr Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases—a phase II, single centre, randomised, pilot study
title_full_unstemmed Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases—a phase II, single centre, randomised, pilot study
title_short Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases—a phase II, single centre, randomised, pilot study
title_sort protocol for the tidal melanoma study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases—a phase ii, single centre, randomised, pilot study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640002/
https://www.ncbi.nlm.nih.gov/pubmed/28988173
http://dx.doi.org/10.1136/bmjopen-2017-016816
work_keys_str_mv AT readtavis protocolforthetidalmelanomastudytopicalimiquimodordiphenylcyclopropenoneforthemanagementofcutaneousintransitmelanomametastasesaphaseiisinglecentrerandomisedpilotstudy
AT webberscott protocolforthetidalmelanomastudytopicalimiquimodordiphenylcyclopropenoneforthemanagementofcutaneousintransitmelanomametastasesaphaseiisinglecentrerandomisedpilotstudy
AT thomasjanine protocolforthetidalmelanomastudytopicalimiquimodordiphenylcyclopropenoneforthemanagementofcutaneousintransitmelanomametastasesaphaseiisinglecentrerandomisedpilotstudy
AT wagelsmichael protocolforthetidalmelanomastudytopicalimiquimodordiphenylcyclopropenoneforthemanagementofcutaneousintransitmelanomametastasesaphaseiisinglecentrerandomisedpilotstudy
AT schaiderhelmut protocolforthetidalmelanomastudytopicalimiquimodordiphenylcyclopropenoneforthemanagementofcutaneousintransitmelanomametastasesaphaseiisinglecentrerandomisedpilotstudy
AT soyerhpeter protocolforthetidalmelanomastudytopicalimiquimodordiphenylcyclopropenoneforthemanagementofcutaneousintransitmelanomametastasesaphaseiisinglecentrerandomisedpilotstudy
AT smithersbmark protocolforthetidalmelanomastudytopicalimiquimodordiphenylcyclopropenoneforthemanagementofcutaneousintransitmelanomametastasesaphaseiisinglecentrerandomisedpilotstudy